Rapport Therapeutics (RAPP) EBITDA (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly EBITDA of -$24.2 million for Q1 2026, up 10.67% year-over-year from -$21.9 million in Q1 2025, and up 37.12% quarter-over-quarter from -$38.5 million in Q4 2025.
Powered by 
Analysis
Rapport Therapeutics (RAPP) EBITDA (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported EBITDA for 4 consecutive years, with -$24.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 10.67% year-over-year to -$24.2 million; the TTM figure through Mar 2026 stood at -$122.2 million (down 31.31% YoY), while the FY2025 annual figure was -$125.1 million, down 50.62% from the prior year.
- EBITDA advanced to -$24.2 million in Q1 2026 per RAPP's latest filing, from -$38.5 million in the prior quarter.
- Across five years, EBITDA topped out at -$6.6 million in Q2 2023 and bottomed at -$38.5 million in Q4 2025.
- Historically, EBITDA has averaged -$21.9 million across 4 years, with a median of -$22.6 million in 2024.
- Annual changes were most pronounced in 2024 — EBITDA slumped 213.73% — and 2026, when it advanced 10.67%.
- Rapport Therapeutics' EBITDA stood at -$14.8 million in 2023, then sank by 58.99% to -$23.5 million in 2024, then sank by 63.72% to -$38.5 million in 2025, then soared by 37.12% to -$24.2 million in 2026.
- Business Quant data shows RAPP's EBITDA at -$24.2 million in Q1 2026, -$38.5 million in Q4 2025, and -$30.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Rapport Therapeutics | 2.22 Bn | 2.22 Bn | - | -60.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.81 Mn |
| Mar 31, 2026 | -24.22 Mn |
| Dec 31, 2025 | -38.51 Mn |
| Sep 30, 2025 | -29.99 Mn |
| Jun 30, 2025 | -29.50 Mn |
| Mar 31, 2025 | -27.11 Mn |
| Dec 31, 2024 | -23.52 Mn |
| Sep 30, 2024 | -21.64 Mn |
| Jun 30, 2024 | -20.80 Mn |
| Mar 31, 2024 | -17.09 Mn |
| Dec 31, 2023 | -14.79 Mn |
| Sep 30, 2023 | -9.56 Mn |
| Jun 30, 2023 | -6.63 Mn |